Epicrispr Biotechnologies Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$8M
- Investors
-
15
Epicrispr Biotechnologies General Information
Description
Developer of a gene expression modulation platform designed to treat complex diseases. The company develops a gene expression modulation System (GEMS) platform that combines epigenomic modulators to control gene expression, enabling healthcare professionals to use customized therapies for specific disease indications.
Contact Information
Website
www.epicrispr.comCorporate Office
- 7000 Shoreline Court
- Suite 100
- San Francisco, CA 94080
- United States
Corporate Office
- 7000 Shoreline Court
- Suite 100
- San Francisco, CA 94080
- United States
Epicrispr Biotechnologies Timeline
Epicrispr Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 19-Oct-2026 | $8M | Completed | Clinical Trials - General | ||
| 3. Later Stage VC (Series C) | 10-Aug-2026 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC (Series B) | 26-Mar-2025 | $75.5M | $131M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 12-Jul-2022 | $55M | $55M | Completed | Clinical Trials - General |
Epicrispr Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A1 | ||||||||
| Seed | 25,510,200 | $0.000010 | 6% | $0.1 | $0.1 | 1x | $0.1 | 19.07% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Epicrispr Biotechnologies Comparisons
Industry
Financing
Details
Epicrispr Biotechnologies Competitors (38)
One of Epicrispr Biotechnologies’s 38 competitors is Arbor Biotechnologies, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arbor Biotechnologies | Venture Capital-Backed | Cambridge, MA | ||||
| Deep Genomics | Venture Capital-Backed | Toronto, Canada | ||||
| Metagenomi Therapeutics | Formerly VC-backed | Emeryville, CA | ||||
| EdiGene | Venture Capital-Backed | Beijing, China | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Epicrispr Biotechnologies Patents
Epicrispr Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025254779-A1 | Engineered epigenetic effectors | Pending | 06-Jun-2024 | ||
| EP-4774383-A1 | Engineered cas12 polypeptides, compositions, and methods of use thereof | Pending | 06-Sep-2023 | ||
| WO-2025054029-A1 | Engineered cas12 polypeptides, compositions, and methods of use thereof | Inactive | 06-Sep-2023 | ||
| WO-2025019273-A1 | Engineered nucleases and guide rna spacer sequences therefor, and compositions, and methods of use thereof | Inactive | 14-Jul-2023 | ||
| EP-4713342-A2 | Systems and methods for regulating target genes | Pending | 17-May-2023 | C12N9/226 |
Epicrispr Biotechnologies Signals
Epicrispr Biotechnologies Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| California Institute for Regenerative Medicine | Government | |||
| Aberdeen Investments (Scotland) | Asset Manager | Minority | ||
| abrdn Healthcare Investors | Hedge Fund | Minority | ||
| Angelini Ventures | Corporate Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority |
Epicrispr Biotechnologies FAQs
-
When was Epicrispr Biotechnologies founded?
Epicrispr Biotechnologies was founded in 2018.
-
Where is Epicrispr Biotechnologies headquartered?
Epicrispr Biotechnologies is headquartered in San Francisco, CA.
-
What is the size of Epicrispr Biotechnologies?
Epicrispr Biotechnologies has 43 total employees.
-
What industry is Epicrispr Biotechnologies in?
Epicrispr Biotechnologies’s primary industry is Discovery Tools (Healthcare).
-
Is Epicrispr Biotechnologies a private or public company?
Epicrispr Biotechnologies is a Private company.
-
What is Epicrispr Biotechnologies’s current revenue?
The current revenue for Epicrispr Biotechnologies is .
-
How much funding has Epicrispr Biotechnologies raised over time?
Epicrispr Biotechnologies has raised $221M.
-
Who are Epicrispr Biotechnologies’s investors?
California Institute for Regenerative Medicine, Aberdeen Investments (Scotland), abrdn Healthcare Investors, Angelini Ventures, and Cormorant Asset Management are 5 of 15 investors who have invested in Epicrispr Biotechnologies.
-
Who are Epicrispr Biotechnologies’s competitors?
Arbor Biotechnologies, Deep Genomics, Metagenomi Therapeutics, EdiGene, and CRISPR Therapeutics are some of the 38 competitors of Epicrispr Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process